Bristol Myers Squibb Company
NEWS
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
BMS announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care (BSC) compared to conventional care, did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia (r/r AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
The drug company plans to combine its Cambridge operations at the laboratory and office building at the site by the end of the first half of 2023.
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program.
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
It was a very busy week for clinical trial updates. Here’s a look.
Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of its checkpoint inhibitor Opdivo (nivolumab).
Eliquis generic was approved by FDA to prevent strokes, blood clots etc. But there were some legal issues which recently got stave off. Know more about it here.
JOBS
IN THE PRESS